Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?
- PMID: 18523768
- PMCID: PMC3124701
- DOI: 10.1007/s00259-008-0842-x
Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?
Comment on
-
Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation.Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1334-42. doi: 10.1007/s00259-007-0711-z. Epub 2008 Mar 12. Eur J Nucl Med Mol Imaging. 2008. PMID: 18335217
References
-
- Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993;13:295–309. - PubMed
-
- Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998;29:128–141. - PubMed
-
- Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129–1133. - PubMed
-
- Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun. 1994;15:806–813. - PubMed
-
- Ichise M, Ballinger JR, Golan H, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med. 1996;37:513–520. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
